The global non-invasive cancer diagnostics market was valued at USD 80.9 billion in 2025 and is expected to reach USD 85.8 billion in 2026. By 2033, the market is projected to expand to USD 139.1 billion, registering a 7.1% CAGR from 2026 to 2033. North America led the global market in 2025, accounting for a 41.2% revenue share.
Market expansion is being supported by the rising prevalence of cancer, continued advances in diagnostic technologies, and increasing efforts by public and private organizations to strengthen early cancer detection and treatment. The growing emphasis on patient-friendly diagnostic approaches is also increasing interest in techniques that can identify disease without invasive procedures.
At a Glance: Market Size and Outlook
2025 market size: USD 80.9 billion
2026 estimated market size: USD 85.8 billion
2033 projected market size: USD 139.1 billion
CAGR, 2026–2033: 7.1%
Leading region in 2025: North America, with a 41.2% revenue share
Fastest-growing region: Asia Pacific
Leading country: U.S.
Grand View Research estimates the global non-invasive cancer diagnostics market at USD 80.87 billion in 2025, with the market expected to increase to USD 85.79 billion in 2026 and reach USD 139.09 billion by 2033, representing a 7.1% CAGR during the forecast period.
What Is Driving Demand for Non-Invasive Cancer Diagnostics?
The increasing global cancer burden is creating a strong need for diagnostic approaches that are accessible, effective, and more comfortable for patients. Detecting cancer at an earlier stage can support timely intervention and improve treatment outcomes and survival prospects. Non-invasive diagnostic techniques can help healthcare providers screen broader populations while reducing the need for complex or painful procedures.
According to the World Health Organization and the International Agency for Research on Cancer, the global burden of cancer is increasing significantly. In 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported worldwide. About 53.5 million people were living within five years of a cancer diagnosis.
The number of new cancer cases is expected to exceed 35 million by 2050, representing a 77% increase. Population aging and growth, along with risk factors including tobacco use, alcohol consumption, obesity, and air pollution, are expected to contribute to this increase. This expanding disease burden is consequently creating greater demand for non-invasive cancer diagnostics across healthcare systems.
Download a free sample report or claim your copy of this full market intelligence report
Where Is the Market Seeing the Strongest Activity?
North America was the largest regional market in 2025, holding 41.2% of global revenue. The U.S. accounted for the largest country-level market share during the same year. Meanwhile, Asia Pacific is expected to record the highest CAGR between 2026 and 2033, highlighting its position as the fastest-growing regional market.
Market Segments Leading in 2025
Product: Instruments accounted for the largest share at 64.4%.
End use: Diagnostic laboratories represented the leading segment with a 53.1% share.
Technology: Imaging held the largest share at 39.9%.
Indication: Liver cancer represented the leading indication, accounting for 16.6%.
Technology Innovation Is Reshaping Cancer Detection
The non-invasive cancer diagnostics market is highly innovation-driven, with companies continuously developing technologies that can detect cancer earlier while minimizing patient discomfort. Advances in liquid biopsy, circulating tumor DNA (ctDNA) analysis, and multi-cancer early detection tests are changing approaches to cancer screening and monitoring.
The integration of artificial intelligence and genomic sequencing is further influencing the diagnostic landscape. These technologies are being used to improve diagnostic accuracy and support more personalized treatment strategies, creating additional opportunities for innovation across cancer detection and monitoring applications.
Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.
Market Entry Remains Technically and Commercially Demanding
Barriers to entry are moderate to high because the development of reliable non-invasive diagnostic tests requires substantial investment in research and development, advanced laboratory infrastructure, and clinical validation. Companies entering the field also need to address intellectual property requirements and develop partnerships with hospitals and diagnostic laboratories to support commercialization.
These requirements create a competitive environment in which technological capabilities, clinical evidence, infrastructure, and strategic collaborations can influence the ability of companies to successfully develop and commercialize diagnostic solutions.
Leading Companies in Non-Invasive Cancer Diagnostics
The study profiles several key companies operating in the global non-invasive cancer diagnostics landscape, including:
Abbott Laboratories
GE HealthCare
Siemens Healthineers AG
Koninklijke Philips N.V.
Canon Medical Systems
F. Hoffmann-La Roche Ltd
Illumina, Inc
Guardant Health, Inc.
Thermo Fisher Scientific Inc.
FONAR Corporation
Explore our dedicated business services:
S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.
Comments
Log in or sign up to join the conversation.